4/A: Citius Oncology CFO Awarded 825,000 Restricted Stock Units

Citius Oncology's Chief Financial Officer, Jaime Bartushak, received a grant of 825,000 restricted stock awards, vesting over three years.

Summary

• Jaime Bartushak, Chief Financial Officer of Citius Oncology, Inc. (CTOR), was granted 825,000 shares of common stock as restricted stock awards.
• The transaction date for this grant was September 19, 2025.
• The shares were acquired at a price of $0, indicating a grant rather than a purchase.
• Following this transaction, Jaime Bartushak beneficially owns 825,000 shares of common stock.
• The restricted stock awards will vest in full on the third anniversary of the grant date, subject to continuous service to Citius Oncology, Inc. or a related entity.

Sentiment

Score: 6

Explanation: The grant of restricted stock to the CFO is a standard executive compensation practice that aligns management interests with shareholders, which is generally positive. However, it also implies future dilution, leading to a neutral-to-slightly-positive sentiment.

Positives

• The grant of restricted stock awards aligns the Chief Financial Officer's long-term interests with those of shareholders, incentivizing sustained company performance.
• This form of compensation serves as a retention mechanism, encouraging the CFO to remain with the company through the vesting period.

Negatives

• The future vesting of these shares will result in dilution for existing shareholders, as new shares will be issued or existing shares will be transferred from a compensation pool.

Risks

• The vesting of the restricted stock awards is contingent upon the Reporting Person's Continuous Service to Citius Oncology, Inc. or a Related Entity, meaning the shares could be forfeited if service is terminated before the vesting date.

Future Outlook

The restricted stock awards are designed to incentivize the Chief Financial Officer's long-term commitment and performance, with full vesting contingent on continuous service through September 19, 2028.

Industry Context

The granting of restricted stock units to key executives is a common practice in the biotechnology and pharmaceutical industries, aiming to align management incentives with long-term shareholder value creation and to retain talent in a competitive environment.

Stakeholder Impact

• Shareholders: Potential future dilution upon vesting of the restricted stock awards, but also improved alignment of management's long-term interests with shareholder value.
• Employees (specifically the CFO): Increased equity stake and long-term incentive for continued service and performance.

Next Steps

• The restricted stock awards will vest in full on the third anniversary of the grant date, September 19, 2028, provided the CFO maintains continuous service.

Key Dates

Keywords

Citius Oncology, CTOR, Restricted Stock Award, Executive Compensation, Insider Ownership, Form 4, Jaime Bartushak, CFO